Syndax Pharmaceuticals (SNDX) Competitors $14.73 +1.28 (+9.52%) Closing price 04:00 PM EasternExtended Trading$14.76 +0.04 (+0.24%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. MRUS, CYTK, AKRO, PTCT, ADMA, TLX, ACAD, KRYS, PCVX, and ACLXShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Merus (MRUS), Cytokinetics (CYTK), Akero Therapeutics (AKRO), PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Vaxcyte (PCVX), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors Merus Cytokinetics Akero Therapeutics PTC Therapeutics ADMA Biologics Telix Pharmaceuticals ACADIA Pharmaceuticals Krystal Biotech Vaxcyte Arcellx Syndax Pharmaceuticals (NASDAQ:SNDX) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Which has more risk & volatility, SNDX or MRUS? Syndax Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SNDX or MRUS? 96.1% of Merus shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, SNDX or MRUS? Merus has higher revenue and earnings than Syndax Pharmaceuticals. Merus is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M53.58-$318.76M-$3.89-3.79Merus$36.13M140.12-$215.33M-$5.50-12.17 Does the media prefer SNDX or MRUS? In the previous week, Merus had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 19 mentions for Merus and 17 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.83 beat Merus' score of 0.34 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is SNDX or MRUS more profitable? Syndax Pharmaceuticals has a net margin of -428.48% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax Pharmaceuticals-428.48% -130.47% -56.12% Merus -685.64%-50.28%-42.00% Do analysts prefer SNDX or MRUS? Syndax Pharmaceuticals currently has a consensus price target of $36.91, suggesting a potential upside of 150.57%. Merus has a consensus price target of $88.50, suggesting a potential upside of 32.21%. Given Syndax Pharmaceuticals' higher possible upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00Merus 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummaryMerus beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$3.08B$5.60B$9.82BDividend YieldN/A2.27%4.60%4.11%P/E Ratio-3.7920.5630.2825.72Price / Sales53.58191.64387.9280.32Price / CashN/A42.0537.7558.93Price / Book8.057.598.456.01Net Income-$318.76M-$54.65M$3.25B$265.06M7 Day Performance15.80%5.43%4.05%2.80%1 Month Performance49.54%6.75%4.32%1.68%1 Year Performance-24.77%31.59%36.25%29.59% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals4.0594 of 5 stars$14.73+9.5%$36.91+150.6%-32.3%$1.27B$23.68M-3.79110News CoverageOptions VolumeMRUSMerus1.861 of 5 stars$63.67-2.9%$88.50+39.0%+31.3%$4.40B$36.13M-11.5637Positive NewsAnalyst RevisionCYTKCytokinetics3.6836 of 5 stars$34.74-1.1%$70.92+104.2%-34.2%$4.15B$18.47M-6.58250Earnings ReportAKROAkero Therapeutics3.9618 of 5 stars$50.62-4.1%$81.57+61.2%+95.0%$4.03BN/A-25.9430News CoverageEarnings ReportInsider TradeAnalyst RevisionPTCTPTC Therapeutics4.449 of 5 stars$50.59-1.5%$69.38+37.2%+51.1%$4.03B$806.78M7.801,410Earnings ReportAnalyst RevisionADMAADMA Biologics4.2874 of 5 stars$16.52-10.9%$27.67+67.5%-0.4%$4.00B$426.45M19.49530TLXTelix PharmaceuticalsN/A$11.76-1.8%$22.33+90.0%N/A$3.98B$516.72M0.00N/AUpcoming EarningsACADACADIA Pharmaceuticals3.7808 of 5 stars$23.800.0%$28.25+18.7%+59.9%$3.96B$957.80M17.40510Analyst RevisionKRYSKrystal Biotech4.5463 of 5 stars$133.95-1.5%$210.22+56.9%-20.3%$3.86B$359.21M27.15210PCVXVaxcyte2.1176 of 5 stars$29.74-9.9%$136.50+358.9%-59.1%$3.85BN/A-7.48160Analyst RevisionACLXArcellx1.8346 of 5 stars$69.28-2.0%$114.31+65.0%+17.1%$3.82B$107.94M-23.1680Earnings ReportAnalyst Revision Related Companies and Tools Related Companies MRUS Alternatives CYTK Alternatives AKRO Alternatives PTCT Alternatives ADMA Alternatives TLX Alternatives ACAD Alternatives KRYS Alternatives PCVX Alternatives ACLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access